Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-N01-OX2
- Development stage
- Preclinical
- Lead developer
- Intellect Neurosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
IN-N01-OX2 is a preclinical-stage antibody-drug conjugate (ADC) developed by Intellect Neurosciences under its CONJUMAB-A platform. It is designed for the treatment of neurodegenerative and retinal diseases, including age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and Alzheimer's disease. The drug consists of a humanized monoclonal antibody (IN-N01, also known as 82E1) targeting the N-terminus of beta-amyloid, chemically conjugated to melatonin (OX2), a small molecule with potent antioxidant, anti-fibrillogenic, and neuroprotective properties. By targeting beta-amyloid, IN-N01-OX2 is intended to promote the clearance of amyloid plaques while simultaneously delivering melatonin to sites of damage to reduce oxidative stress and inflammation, potentially avoiding side effects like vasogenic edema.
- Other names
- N01-OX2N-01-OX2N 01-OX2
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on IN-N01-OX2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-N01-OX2.